1. Home
  2. Media
  3. News
  4. Bioiberica to launch Hialsorb® Intraarticular, a hyaluronic acid injection for the treatment of pain and inflammation associated with osteoarthritis

Bioiberica to launch Hialsorb® Intraarticular, a hyaluronic acid injection for the treatment of pain and inflammation associated with osteoarthritis

5 Apr 2017
Healthcare
  • Hialsorb Intraarticular restores viscosity and elasticity of synovial fluid
  • Its natural, highly pure hyaluronic acid allows for an excellent tolerability 

 

Hyaluronic acid is a biomolecule naturally present in the human body. It is particularly present in the joint’s synovial fluid, which acts as a lubricant for cartilage and ligaments, facilitating movement. Age and overuse caused by certain jobs or sports involving repeated impacts reduces the amount of hyaluronic acid in our joints. This reduction in the level of hyaluronic acid decreases its shock-absorbing ability and results in more wear and tear to the joint, which amounts to increased pain and loss of mobility.

Bioiberica launched Hialsorb® Intraarticular, a hyaluronic acid injection for the treatment of osteoarthritis-associated pain and inflammation. With this new release our biotech company increases their range of specialized products for joint care. Hialsorb® Intraarticular is a single-application injection which restores the viscosity and elasticity of synovial fluid, thus reducing pain and inflammation, increasing mobility and decreasing friction.

Furthermore, the hyaluronic acid of Hialsorb® Intraarticular is of natural origin-it is not mixed with other chemical agents. Through a strict production process, we obtain a highly pure compound which guarantees excellent tolerability by the human body.